Ann: iPPS SIGNIFICANT OA PAIN REDUCTION AT 12 MONTHS, page-157

Whilst MPS potential partnering discussions are stated as "well advanced" I'm quietly confident PAR flagging China for a regional OA partner deal is just as likely given the tenacity of Angel Pond. As PAR has noted Angel Pond is a China based facilitator of pharma partnering activities.

The Chinese market is well developed and growing at a rapid click. Nearly all the BP have a strong and growing presence inside of China for a reason. The reimbursement for drugs related to chronic conditions is higher, flexible manufacturing and modest clinical testing requirements on Chinese nationals that could be readily incorporated into our exiting programs. On an equivalent basis to our current TAM ( for AUS, US, EU5) the Chinese OA TAM is larger than the US by a considerable margin (just under double).

Looking for an early Christmas present to surprise the market (and shorters).